The presentation summarizes the latest updates for the analysis of biopharmaceuticals using the Agilent 1290 Infinity II 2D-LC Solution. After a short introduction to the principle mode of operation, I will explain the latest 2D-LC modes; multiple heart-cutting and high-resolution sampling (HiRes). In the following, four case studies are presented for the analysis of intact and digested proteins samples. Two studies focus on peptide mapping using comprehensive 2D-LC for the identification of monoclonal antibody mutation sites with Q-TOF LC/MS detection, and on the characterization of antibody-drug conjugates and the assigning of drug conjugation sites. Beyond the capabilities of increasing peak capacity, the Agilent 1290 Infinity 2D-LC solution offers solutions for automated desalting before MS analysis as is demonstrated in the 2D-LC/MS characterization of charge variants using ion exchange and reversed-phase chromatography. Further, the Agilent 1290 Infinity 2D-LC solution finds implementation options in the process control of monoclonal antibodies which is shown for the 2D-LC analysis using combinations of Protein A quantification in combination with aggregation or charge variant analysis.
Separation Science, in collaboration with Agilent Technologies, has developed an eSeminar covering the analysis of biotherapeutics and biosimilars.
This presentation is given by Sonja Schneider (Manager Application Development, Agilent Technologies)
By attending this presentation you will learn about...
- New Modes available for the Agilent 1290 Infinity II 2D-LC Solution
- The Agilent 1290 Infinity II 2D-LC Solution is well suited for intact as well as digested protein analyses
- The Agilent 1290 Infinity II 2D-LC Solution is more than just increasing peak capacity